KRSA logo

KORSANA BIOSCIENCES INC

KRSANASDAQ
Earnings Nov 11US Equity
$34.10▲ $3.65 (+10.71%)
After hours · at close
🔔
Track KRSA
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 10.7%
7d▼ 2.2%
14d▲ 8.0%
30d▲ 27.9%
ytd▲ 286.6%
1y▲ 108.6%
🏦Market Cap
$194.46B
Mid Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
56
Weak

Trading Snapshot

Day Range
$33.87 – $34.33
52-Week Range
$21.00 – $37.27
Volume
$2.33B
Avg Volume
$3.01B
Shares Outstanding
—
Next Earnings
Oct 31, 2026

Fundamentals Snapshot

Annual Revenue
$2M
Last Q Revenue
$517,121
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
—
Dividend Yield
—
Dilution (1yr)
+26.7%

Why Investors Own KRSA

  • ✓High-growth profile — revenue up +41.6% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 73% gross margin and 29% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

KRSA logo

KORSANA BIOSCIENCES INC

KRSA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$2M▲ +3.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$5M▲ +37.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$3M▼ −23.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
461K▲ +26.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$3M▲ +$8K YoY
StockOtter · stockotter.space

About KORSANA BIOSCIENCES INC

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate. The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
56/100

Analyst Price Target

ⓘ
Average Target
$36.39
▲ +6.7% Upside
High Target$40.18
Low Target$28.51
Based on 10 analysts

Latest News & Updates

🚀
MarketWatch·2h ago

KORSANA BIOSCIENCES INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Barron’s·5h ago

Analysts lift KRSA price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

KORSANA BIOSCIENCES INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.